| Similar Articles |
|---|
 |
The Motley Fool
October 11, 2011
Arlene Weintraub |
Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage An unprecedented cancer drug development deal.   |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
January 28, 2011
Brian Orelli |
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. |
The Motley Fool
September 24, 2007
Brian Lawler |
An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
January 13, 2009
Brian Orelli |
Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
Chemistry World
July 8, 2015
Phillip Broadwith |
Celgene backs immunotherapy with Juno collaboration US biopharmaceutical firm Celgene is to bolster its position in the emerging field of cell therapy through a collaboration with biotech Juno Therapeutics. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
The Motley Fool
February 23, 2011
Brian Orelli |
Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug. |
The Motley Fool
April 30, 2010
Brian Orelli |
New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene. |
The Motley Fool
January 11, 2010
Brian Orelli |
Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well. |
The Motley Fool
April 1, 2009
Brian Orelli |
Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Chemistry World
December 4, 2013
Phillip Broadwith |
Celgene buys into anticancer antibodies US firms Celgene and OncoMed have tied up a deal to develop and commercialize biological therapies for cancer. |
The Motley Fool
February 6, 2007
Brian Lawler |
Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook. |
Chemistry World
July 29, 2015
Phillip Broadwith |
Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
The Motley Fool
April 28, 2011
Brian Orelli |
Celgene Gets No Love The market shrugs off a solid quarter. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
March 26, 2008
Brian Lawler |
Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population. |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
May 8, 2007
Brian Lawler |
Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
The Motley Fool
June 30, 2010
Brian Orelli |
Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term. |
The Motley Fool
October 30, 2006
Brian Lawler |
Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note. |
The Motley Fool
March 22, 2005
Charly Travers |
Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials. |
The Motley Fool
November 30, 2007
Brian Lawler |
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM... |
BusinessWeek
February 16, 2004
Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
The Motley Fool
October 23, 2009
Brian Orelli |
Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
Chemistry World
November 22, 2013
Emily James |
100 million for cancer research centers Cancer Research UK has invested 100 million pounds in 15 innovative research centers, acquiring high level expertise to solve the latest challenges in cancer. |
The Motley Fool
June 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap. |
